Harris M, Back D, Kewn S, et al. Intracellular carbovir triphosphate levels in patients taking abacavir once a day

University of Liverpool, Liverpool, England, United Kingdom
AIDS (Impact Factor: 5.55). 06/2002; 16(8):1196-7. DOI: 10.1097/00002030-200205240-00021
Source: PubMed
6 Reads
  • Source
    • "Using the same method, Harris et al studied CBV-TP levels in peripheral mononuclear cells (PBMCs) of 5 HIV-positive adults taking ABC 600 mg once a daily for 5 to 17 months as a component of multiple drug rescue therapy. It was shown that the half life of CVB-TP was greater than 12 hours.8 A slightly larger study than that done by Harris et al was carried out by Piliero et al involving twenty patients given ABC 300 mg dose over a 24-hour period. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abacavir has been at the center of research and clinical interest in the last two years. The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially since the introduction of routine testing for the HLA-B*5701 allele; the activity of the drug in HIV-infected persons with HIV RNA values more than 100,000 copies/mL has been questioned; the possible increased risk of myocardial infarction after recent exposure to abacavir has been debated; and the drug has been moved from the "recommended" category to the "alternative" category in several guidelines. Still, the drug remains a useful agent in combination with other drugs, including lamivudine, for the treatment of HIV infection. This review will focus on the pharmacokinetics, activity, side effects, and resistance profile of both abacavir and lamivudine, including a thorough review of all of the recent studies relevant to both drugs.
    Therapeutics and Clinical Risk Management 03/2010; 6(1):83-94. · 1.47 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nucleoside and nucleotide analogues are essential for the design of effective antiretroviral regimens. There are currently many options for the selection of such drug backbones, although not all combinations will display optimal results. The concomitant administration of certain drugs should be avoided due to high rates of toxicity (ddl/d4T, ddl/TDF), antagonism (AZT/d4T, 3TC/FTC) and/or a greater risk of virological failure (ddl/TDF, ABC/TDF). The understanding of the plasmatic and intracellular metabolism of nucleoside/nucleotide analogues is crucial for deciding the optimal posology of each drug and the better dual combinations to be selected. Interferences between the pathways involved into the intracellular activation of some nucleoside/nucleotide analogues may help to understand why certain drug combinations should be avoided.
    AIDS reviews 10/2004; 6(4):234-43. · 3.79 Impact Factor
Show more